Protein
Description 2442 amino acids; 265351 Da; predict PI=8.83; Known domains are: KIX= CREB binding, Bromo= Bromodomain, Zn=zinc-finger (corresponding to cysteine-histidine rich regions), HAT= acetyl transferasic, Q= poly Glutaminic stretch. From the carboxy to the N-terminus: Q-Zn-HAT-Zn-Bromo-KIX-Zn. Reported isoform b (2402 aa) lacking aa406-444 (exon 5). Methylation of the KIX domain by CARM1 blocks association with CREB. Phosphorylated upon DNA damage, probably by ATM or ATR.
Expression
Wide expression; expression in the whole embryo as well brain; cDNA sources: mammary gland; lung; placenta; testis; lymph node; thymus; mouth; ear; kidney; embryonic tissue; larynx; pancreas; intestine; blood; heart; amniotic fluid; trachea; liver; thyroid; skin; connective tissue; uterus; eye; prostate; stomach; ovary; salivary gland; muscle; adrenal gland; bone marrow; adipose tissue; spleen; nerve; bone; bladder.
Localisation
Nucleus.
Function
Binds specifically to phosphorylate CREB and enhances its transcriptional activity toward cAMPresponsive genes; Acts as transcription co-activator by: i) enabling the interaction between different TF and RNAPolII complexes, ii) serving as molecular scaffold that brings enzymes to the promoter, iii) remodelling the chromatin favouring the open status, by histone and non-histone proteins acetylation. Essential role in embryogenesis, cell differentiation, apoptosis, and proliferation; Involved in the regulation of cell cycle during G1/S transition.
Homology

EP300
Implicated in t(8;16)(p11;p13)/M4 ANLL --> MOZ/CBP
Disease Acute non lymphocytic leukemia (ANLL) and treatment related ANLL (t-ANLL). Prognosis Poor: remission is obtained in half cases; survival is often less than 1yr. Cytogenetics +8 as an additional anomalies in half cases. Hybrid/Mutated gene 5' MOZ -3' CBP. Abnormal protein N-term finger motifs and acetyl transferase from MOZ fused to most of CBP, with a breakpoint in 5' of the CREB binding domain of CBP. 
Abnormal protein
In-frame fusion between MYST4 exon 17 and CREBBP exon 3. Variants fusing MYST4 exon 16 and CREBBP exon 5; MYST4 exon 17 and CREBBP exon 7 have been also described. CREBBP-MYST4 transcripts have been detected.
t(11;16)(q23;p13)/t-ANLL --> MLL/CBP
Disease Therapy related ANLL (t-ANLL); should be very close to the t(11;22)(q23;q13).
Prognosis
Likely to be poor. Hybrid/Mutated gene 5' MLL -3'CBP. Abnormal protein N-term AT hook and DNA methyltransferase from MLL fused to most of CBP; variable brakpoint in CBP: either 5' to the CREB binding domain (like in the t(8;16)), or just upstream the bromodomain.
Rubinstein-Taybi syndrome
Note
Due to CBP haploinsufficiency. Disease Rare autosomal dominant congenital disorder characterized by postnatal growth retardation and psychomotor developmental delay, skeletal anomalies (broad and duplicated distal phalanges of thumbs and halluces are a landmark sign) and specific facial dysmorphisms. The latter include down-slanted palpebral fissures, broad nasal bridge, beaked nose and micrognathia. In addition, patients with RSTS have an increased, although not well documented, risk of tumor formation.
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